Goflikicept for Resolution and Prevention of Attacks in Pediatric and Adolescent Patients With Colchicine-Resistant or Colchicine-Intolerant Familial Mediterranean Fever
Key facts
- Who runs it
- R-Pharm
- Where
- Russia3 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 3
- People taking part
- 18 people, planned
- Starts
- Dec 2026
- Expected to end
- Apr 2030
- Type of study
- Interventional
- Treatments tested
- RPH-104
- Record updated
- 19 October 2026
Who can take part
- Age
- 5 years to 17 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- Confirmed diagnosis of Familial Mediterranean Fever (FMF) based on new diagnostic criteria of the Eurofever/PRINTO expert group (2019)
- Male and female participants aged ≥ 5 and < 18 years at the time of signing Informed Consent Form (ICF) and Visit 1, respectively:; 2.1. In Kingdom of Saudi Arabia, the upper age limit is 14 years (i.e. the participants should be between ≥ 5 and ≤ 14 years old); 2.2. In other countries, the upper age limit is 18 years (i.e. the participants should be between ≥ 5 and < 18 years old)
- Availability of a voluntarily signed and dated ICF for participation in this study: the informed consent of the parent or legal representative and the consent of the child
- Availability of one of the documented data listed below (at the time of the start of screening) (records of medical examinations/consultations including those done by the investigator, hospital discharges) confirming:; 4.1. colchicine resistance at the maximum tolerated therapeutic dose (depending on age and weight) confirmed by the persistence of at least one attack of the disease per month on average, despite the indicated therapy for at least the last 3 months before the start of screening. Colchicine administration will be continued at stable dose if it is not associated with unacceptable adverse drug reactions; 4.2. intolerance to therapeutic or subtherapeutic doses of colchicine (presence of unacceptable adverse drug reactions). The dose of colchicine should be stable for at least 5 days before the participant is enrolled (before screening)
- Ability of the participant and the parent (legal representative) and willingness, in the reasoned opinion of the investigator, to visit the study site during all scheduled visits, to perform the study-related procedures and comply with the Protocol requirements including consent to undergo subcutaneous injections by qualified personnel of the site
- One active attack with a duration of no more than 2 days (48 hours) at the time of Visit 1 defined as the development of both clinical and serological signs of an attack including:; Physician's Global Assessment (PGA) score ≥ 2 suggesting "mild", "moderate", or "severe" disease activity (i.e. clinical signs); C-reactive protein (CRP) level > 10 mg/L (i.e. serological signs)
- The Russian Federation, the Hashemite Kingdom of Jordan and the Republic of Turkey: Consent of female adolescents, after menarche, to use highly effective contraceptives throughout the study, starting from the screening (signing ICF) and for at least 8 weeks after completion (termination) of the study therapy; as well as the presence of a negative pregnancy test (serum test for chorionic human gonadotropin (HCG)) OR Consent of sexually active male adolescents to use highly effective contraceptives throughout the study, starting from the screening (signing ICF) and for at least 8 weeks after completion (termination) of the study therapy
Who cannot take part
- Administration of live (attenuated) vaccine less than 3 months prior to Visit 1 (treatment period initiation) and/or necessity to use such vaccine within 3 months after GFC discontinuation
- Conditions or signs which, according to the investigator, suggest impaired (reduced) immune response and/or significantly increase the risk of immunomodulating therapy including (but not limited to):; 3.1. any acute or chronic active infection at the time of screening, an infection requiring antimicrobial therapy within 4 weeks prior to screening, or a history of serious, opportunistic, or frequently recurring infection within 6 months prior to screening; 3.2. presence of infection caused by the human immunodeficiency virus (HIV), hepatitis B virus or hepatitis C virus
- Any other relevant concomitant diseases or conditions that, in the Investigator's judgment, may affect the participant's participation or well-being in the study and/or interfere with the assessment of study results
- Surgical intervention within 8 weeks prior to the screening or planned for the period of participation in the study, which, in the investigator's opinion, agreed with the Sponsor, will generate an unacceptable risk for the participant
- Any existing malignant neoplasm during the screening period or within 5 years prior to screening, including blood and lymphatic neoplasm, except non-metastatic basal cell and squamous cell skin cancer after complete resection or carcinoma in situ of any type after complete resection
- Previous administration of:; rilonacept - less than 6 weeks prior to Day 0 of the study; canakinumab - less than 12 weeks prior to Day 0 of the study; anakinra - less than 72 hours prior to Day 0 of the study; rituximab - less than 24 weeks before day 0; tumor necrosis factor (TNF) inhibitors, IL-6 inhibitors and other biological medications with an immunosuppressive mechanism of action - less than 6 weeks or 5 half-lives (whichever is longer) before study day 0; immunosuppressants (azathioprine, leflunomide, dapsone, cyclosporine, mycophenolate mofetil, tacrolimus, sirolimus, mercaptopurine, methotrexate, etc.) - less than 4 weeks or 5 elimination half-lives (whichever is longer) before study day 0. In case of leflunomide administration complete elimination course using cholestyramine should be documented; intravenous (IV) immunoglobulin (Ig) - less than 8 weeks before day 0; intravenous administration of glucocorticoids - less than 1 week (from the end of therapy) to study day 0; intramuscular, intra-articular or periarticular administration of glucocorticoids - less than 4 weeks before day 0; systemic oral glucocorticoid therapy at doses > 0.2 mg/kg/day of prednisolone equivalent on day 0; changes in the dose/treatment regimen of oral glucocorticoids during the 4 weeks prior to the screening
- Concomitant participation in other clinical studies at the screening onset or administration of any unauthorized (investigational) medications less than 4 weeks or 5 half-life periods (whichever is longer) before Visit 1 (treatment initiation)
- Prior participation in this clinical study in case of at least one GFC dose
- Hypersensitivity to GFC and/or its components/excipients
- History of active or latent tuberculosis (TB) or existing risk factors or signs suggestive of active or latent M. tuberculosis including (not limited to) the following:; 4.1. living or working in specific conditions that increase the risk of contact with participants with TB, such as residential care, places of deprivation of liberty, communities of persons without a special place of residence, etc. during the last year before the start of the treatment period; 4.2. close contact, i.e. living at the same premises (at home or in another enclosed environment) for a prolonged period of time (several days or weeks, rather than minutes or hours) with a person with active pulmonary TB during the last year before the start of the treatment period; 4.3. results of examinations indicating active or latent infection with M. tuberculosis: positive QuantiFERON-TB / T-SPOT.TB test at screening; chest Xray/CT findings confirming pulmonary TB during screening
- History of organ transplantation or necessity in transplantation at the screening onset
- History of alcohol or psychoactive substances abuse, according to the investigator's evaluation
- Any of the deviations in the laboratory tests below:; neutrophil count < 1.5×10\^9/L (< 1500/mm\^3); white blood cell (WBC) count < 3×10\^9/L (< 3000/mm\^3); platelet count < 100×10\^9/L (< 100 000/mm\^3 or < 100 000×10\^6/L); ALT and/or AST ≥ 2.0 × upper limit of normal (ULN); if ALT and/or AST is ≥ 2 × ULN but < 3 × ULN at the screening, retest is allowed; bilirubin > 1.5 x ULN (except for confirmed Gilbert's disease)
- Severe renal failure: Glomerular filtration rate (GFR) calculated by Schwartz formula is < 45 mL/min/1.73 m\^2
- Pregnancy or breast-feeding
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 5 and 17 years old?
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The primary objective is to evaluate the main pharmacokinetic (PK) parameters, efficacy, and safety of goflikicept (GFC) in children and adolescents with colchicine-resistant or colchicine-intolerant familial Mediterranean fever (FMF).
The group in the trial
- RPH-104Treatment being tested
RPH-104 subcutaneously at 2.2 mg/kg on Day 0, followed by 1.1 mg/kg on Days 7 and 14 and then every 2 weeks (q2w). The dose may be increased to 2.2 mg/kg q2w (maximum 160 mg) in non-responders or participants with recurrent familial Mediterranean fever (FMF) attacks.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- International, Multicenter, Open-label Clinical Study of Goflikicept for Resolution and Prevention of Attacks in Pediatric and Adolescent Participants With Familial Mediterranean Fever With Resistance to or Intolerance of Colchicine
- Criteria questions
- Built from NCT07880886, who can take part
- Record updated
- 19 October 2026